Radium 223

RADIATION3 trials

Sponsors

Gustave Roussy, Cancer Campus, Grand Paris, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Tufts Medical Center

Conditions

Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)Metastatic Castrate Resistant Prostate CancerProstate CancerThyroid Cancer

Phase 1

A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer

WithdrawnNCT02396368

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBone-only Metastatic Castration-Resistant Prostate Cancer (CRPC), Prostate Cancer

Start: 2015-03-31End: 2017-07-31Updated: 2015-11-20

Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer

CompletedNCT03737370

Tufts Medical CenterMetastatic Castrate Resistant Prostate Cancer

Start: 2018-01-30End: 2025-09-30Updated: 2025-10-07

Phase 2

Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer

CompletedNCT02390934

Gustave Roussy, Cancer Campus, Grand ParisThyroid Cancer

Start: 2014-10-01End: 2019-04-02Updated: 2019-06-11

Related Papers

Dose-Dense Docetaxel and Radium-223 in Bone-Dominant Metastatic Castration-Resistant Prostate Cancer.

2025-04-29

Fractionated docetaxel (D) and radium 223 (Ra223) in metastatic castration-resistant prostate cancer (CRPC): A modular phase I trial.

Journal of Clinical Oncology2024-06-011 citations

AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)

Frontiers in Medicine2022-11-1840 citations

RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer

European Journal of Nuclear Medicine and Molecular Imaging2021-02-2315 citations

Fractionated docetaxel and radium-223 (Ra223) in metastatic castration-resistant prostate cancer (CRPC): A phase I trial.

Journal of Clinical Oncology2021-02-201 citations